medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Number 1

<< Back Next >>

Ann Hepatol 2018; 17 (1)

Clinical Findings of HCV Chronic Infection in Undocumented Immigrants and Low-Income Refugees in Three Areas of Southern Italy

Sagnelli E, Alessio L, Sagnelli C, Gualdieri L, Pisaturo M, Minichini C, Di Caprio G, Starace M, Onorato L, Scotto G, Macera M, Coppola N

Language: English
References: 40
Page: 47-53
PDF size: 144.25 Kb.


ABSTRACT

Introduction and aim. In recent decades, Italy has become a land of immigration from countries suffering a socio-economic crisis. The aim of this study was to perform an organized screening to identify and offer care to immigrants with HCV infection. Material and methods. The screening, performed from 2012 to 2015, involved 1,727 immigrants in the Campania and Apulia regions in southern Italy. Results. Screening was accepted by 1,727 (85%) out of 2,032 immigrants interviewed; 70 (4.1%) of the 1,727 were anti-HCV-positive, all unaware of their serological condition, 31 (44.3%) of whom were HCV-RNA-positive and 39 negative. The 31 HCV-RNA-positive immigrants were further investigated at a third-level clinic of infectious diseases. The HCV viral load was 2.6 x 107±7.7 x107 IU/mL, and 35.5% showed HCV-genotype 1a or 1b, 23.8% genotype 2 and 22.6% genotype 3. Two immigrants had liver cirrhosis and, in accordance with the Italian Healthcare Authority guidelines, received an interferon-free regimen and achieved a sustained virological response (SVR); 18 had chronic hepatitis, 6 of whom with a high risk of progression and received interferonbased therapy, with SVR in 4, whereas 12 at low risk were put on a waiting list for future interferon-free treatment, once licensed. The remaining 11 HCV-RNA-positive immigrants were considered HCV inactive chronic carriers and were included in a long-term observational program. Conclusion. The screening program can be considered successful since it was accepted by 85% of the subjects interviewed and identified 70 anti-HCV-positive immigrants, all unaware of their clinical and virological condition.


REFERENCES

  1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-67.

  2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age specific antibody to HCV seroprevalence. Hepatol 2013; 57: 1333-42.

  3. Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44: 20-9.

  4. McHutchison JG, Bacon BR. Chronic hepatitis C: an age wave of disease burden. Am J Manag Care 2005; 11: S286- S295; quiz S307-S311.

  5. WHO Guidelines Approved by the Guidelines Review Committee. Guidelines for the screening, care and treatment of persons with hepatitis C infection. Geneva: World Health Organization, 2014. Available from: http://apps.who.int/medicinedocs/ documents/s22180en/s22180en.pdf

  6. El Khoury AC, Wallace C, Klimack WK, Razavi H. Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas. J Med Econ 2012; 15: 887-96.

  7. Sagnelli E, Pisaturo M, Stanzione M, Messina V, Alessio L, Sagnelli C, Starace M, et al. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C. Clin Gastroenterol Hepatol 2013; 11: 1174-80.

  8. Petruzziello A, Coppola N, Diodato AM, Iervolino V, Azzaro R, Di Costanzo G, Di Macchia CA, et al. Age and gender distribution of hepatitis C virus. Itervirology 2013; 56: 206-12.

  9. Rao MR, Naficy AB, Darwish MA, Darwish NM, Schisterman E, Clemens JD, Edelman R. Further evidence for association of hepatitis C infection with parenteral schistosomiasis treatment in Egypt. BMC Infect Dis 2002; 4: 2-29.

  10. Averhoff FM, Glass F, Holtzman Global D. Burden of Hepatitis C: Considerations for Healthcare Providers in the United States. Clin Infect Dis 2012; 55 (Suppl. 1): S10-S15.

  11. Shire AM, Sandhu DS, Kaiya JK, Oseini AM, Yang JD, Chaiteerakij R, Mettler TA, et al. Viral hepatitis among Somali immigrants in Minnesota: association of hepatitis C with hepatocellular carcinoma. Mayo Clin Proc 2012; 87: 17-24.

  12. Available from: http://ec.europa.eu/dgs/home-affairs/whatwedo/ networks/european_migration_network/reports/docs/ annualpolicy/2014/00.emn_annual_report_on_immigration _and_asylum_synthesis_report.pdf.

  13. Caritas and Migrantes. XXIV Rapporto Immigrazione 2014. (XXIV report on immigration 2014). Rome: Caritas and Migrantes; June 2015. p.1-25. Italian. Available from: http:// www.caritasitaliana.it/materiali//Pubblicazioni/libri_2015/ Rapporto_Immigrazione/sintesi_rapportoimmigrazione2014 _quadroregionale.pdf

  14. Greenaway C, Thu Ma A, Kloda LA, Klein M, Cnossen S, Schwarzer G, Shrier I. The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis. PLoS One 2015; 10: e 0141715. Review. Erratum in: PLoS One 2015; 10: e0144567.

  15. Greenaway C, Ma AT, Kloda LA, Klein M, Cnossen S, Schwarzer G, Shrier I. Correction: The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis. PLoS One 2015; 10: e0144567.

  16. Coppola N, Alessio L, Gualdieri L, Pisaturo M, Sagnelli C, Caprio N, Maffei R, et al. Hepatitis B virus, hepatitis C virus and human immunodeficiency virus infection in undocumented migrants and refugees in southern Italy, January 2012 to June 2013. Euro Surveill 2015; 20: 30009.

  17. Lam BP, Jeffers T, Younoszai Z, Fazel Y, Younossi ZM. The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Therap Advan Gastroenterol 2015; 8: 298-312.

  18. Coppola N, Pisaturo M, Zampino R, Macera M, Sagnelli C, Sagnelli E. Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals. World J Gastroenterol 2015; 21: 10749-59.

  19. Coppola N, Minichini C, Starace M, Sagnelli C, Sagnelli E. Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals. J Med Virol 2016.

  20. Costantino A, Spada E, Equestre M, Bruni R, Tritarelli E, Coppola N, Sagnelli C, et al. Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C. Virol J 2015; 12: 186.

  21. Bernabucci V, Ciancio A, Petta S, Karampatou A, Turco L, Strona S, Critelli R, et al. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women. World J Gastroenterol 2014; 20: 16726-33.

  22. Coppola N, Pisaturo M, Sagnelli C, Sagnelli E, Angelillo IF. Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors. PLoS One 2014; 9: e94542.

  23. Coppola N, De Pascalis S, Pisaturo M, Paradiso L, Macera M, Capoluongo N, Alessio L, et al. Sustained virological response to antiviral treatment in chronic hepatitis C patients may be predictable by HCV-RNA clearance in peripheral blood mononuclear cells. J Clin Virol 2013; 58: 748-50.

  24. Sagnelli E, Starnini G, Sagnelli C, Monarca R, Zumbo G, Pontali E, Gabbuti A, et al. Blood born viral infections, sexually transmitted diseases and latent tuberculosis in italian prisons: a preliminary report of a large multicenter study. Eur Rev Med Pharmacol Sci 2012; 16: 2142-6.

  25. Sagnelli E, Stroffolini T, Sagnelli C, Smedile A, Morisco F, Furlan C, Babudieri S, et al. Epidemiological and clinical scenario of chronic liver diseases in Italy: Data from a multicenter nationwide survey. Dig Liver Dis 2016; 26. pii: S1590-8658(16)30431-5.

  26. Affronti M, Affronti A, Soresi M, Giannitrapani L, Campagna E, Tramuto F, Brunor G, et al. Distribution of liver disease in a cohort of immigrants in Sicily: analysis of day-hospital admissions in a migration medicine unit. Inf Med 2014; 3: 200-5.

  27. Sagnelli E, Taliani G, Castelli F, Bartolozzi D, Cacopardo B, Armignacco O, Scotto G, et al. Chronic HBV infection in pregnant immigrants: a multicenter study of the Italian Society of Infectious and Tropical Diseases. New Microbiol 2016; 39: 114-8.

  28. Filippini P, Coppola N, Pisapia R, Scolastico C, Marrocco C, Zaccariello A, Nacca C, et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS 2006; 20: 1253-60.

  29. Gaiani S, Gramantieri L, Venturoli N, Piscaglia F, Siringo S, D’Errico A, Zironi G, et al. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. J Hepatol 1997; 27: 979-85.

  30. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona- 2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-30.

  31. Available from: http://www.easl.eu/research/our-contributions/ clinical-practice-guidelines/detail/easl-recommendations- on-treatment-of-hepatitis-c-2016

  32. Available from: http://www.webaisf.org/pubblicazioni/documento- aisf-hcv-2016.aspx

  33. Pottie K, Greenaway C, Wong D, Assayag D, Deschenes M, Hui C, Ueffing E, et al. Evidence based clinical guidelines for immigrants and refugees. Can Med Assoc J 2011; 183: E824-E925.

  34. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, Brouwer JT, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatol 1994; 19: 1321-4.

  35. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. Global distribution and prevalence of hepatitis C virus genotypes. Hepatol 2015; 61: 77-87.

  36. Murphy DG, Willems B, Deschênes M, Hilzenrat N, Mousseau R, Sabbah S. Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5’ untranslated region sequences. J Clin Microbiol 2007; 45: 1102-12.

  37. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61: S45-S57.

  38. Coppola N, Pisaturo M, Sagnelli C, Onorato L, Sagnelli E. Role of genetic polymorphisms in hepatitis C virus chronic infection. World J Clin Cases 2015; 3: 807-22.

  39. Pietrogrande M, De Vita S, Zignego AL, Pioltelli P, Sansonno D, Sollima S, Atzeni F, et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virusinfected patients. Autoimmun Rev 2011; 10(8): 444-54.

  40. Conca P, Cafaro G, De Renzo A, Coppola A, Cimino E, Tarantino G. Successful and Safe Long-Term Standard Antiviral Therapy in a Patient with “Explosive” Immune Response in Course of HCV-Related Liver Cirrhosis. Int J Mol Sci 2015; 16: 14075-85.




2020     |     www.medigraphic.com